Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury

New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation with TBI

HOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that Company’s abstract, titled: “MEG Source Imaging Reveals Neuronal Changes in Combat-Related Mild Traumatic Brain Injury after Transcranial Electrical Stimulation using Nexalin,” has been accepted for a poster presentation at the upcoming 2023 Military Health System Research Symposium (MHSRS) being held on August 14-17, 2023 at the Gaylord Palms Resort and Convention Center, Kissimmee, Florida, USA.

The abstract was accepted under the breakout session: Mental Health and Traumatic Brain Injury. The poster for this breakout session will be presented in Poster Session 2 on Tuesday, August 15, 2023. The poster will be available on the MHSRS website after the meeting.

Mild traumatic brain injury (mTBI) is a leading cause of sustained physical, cognitive, emotional, and behavioral deficits in veterans and the general public. According to Global Market Insights, the Traumatic Brain Injuries Assessment Market size was valued at approximately $3.3 billion in 2022 and is projected to reach over $7.2 billion in 2032.

The abstract describes the study using Magnetoencephalography (MEG) to assess the neuronal changes in veterans with combat-related mTBI after treatment delivered by Nexalin’s non-invasive, frequency-based, deep-brain stimulation device. The reduction of hyperactivity of delta- and gamma-band activities in mTBI suggests the Nexalin treatment can reduce deafferentation and GABA-ergic inhibitory interneuron dysfunctions in chronic mTBI. Moreover, none of the veterans reported adverse effects. The data supports the Company’s strategy to offer military and civilian physicians a new tool to effectively treat mTBI without the use of medication, and without side effects or adverse events.

A prior clinical study of adult patients with chronic insomnia, evaluating Nexalin’s non-invasive, frequency-based deep-brain stimulation device, was performed in the Laboratory of Neuromodulation, Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China, which demonstrated statistically significant improvements among patients. According to an article in Science Direct, sleep disturbance is common following traumatic brain injury (TBI), affecting 30–70% of individuals, many occurring after mild injuries.